Clinical trial · Observational
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone. During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results. No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.
Conditions
Conditions (13)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Cancer Metastatic | — | UNRESOLVED | — |
| Bone Cancer Tumor | — | UNRESOLVED | — |
| Bone Tumors | Bone Neoplasm | ALIAS | 0.90 |
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Kidney Tumors | Kidney Neoplasm | ALIAS | 0.90 |
| Liver Cancer (Primary and Metastatic) | Malignant Liver Neoplasm | CURATED_EXACT | 0.85 |
| Lung Cancer (Diagnosis) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Lung Tumors | Lung Neoplasm | ALIAS |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Local tumor control
- timeFrame
- 6 months, 1 year, 2 years, 3 years
- description
- Local tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.
Secondary outcomes (5)
- measure
- Overall survival
- timeFrame
- 6 months, 1 year, 2 years, 3 years
- description
- Time from the index procedure to death from any cause.
- measure
- Progression-free survival
- timeFrame
- 6 months, 1 year, 2 years, 3 years
- description
- Time from the index procedure to disease progression or death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years; * Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors; * Use of spectral angio-CT image guidance as part of standard care; * Written confirmed consent. Exclusion Criteria: * Patients who are declared incapacitated; * Patients suffering from psychic disorders that make a comprehensive judgement impossible.
References
Publications (0)
Data not yet available